A Deal for Teal

A Deal for Teal

We are pleased to announce another special deal happening right now over at Lee’s Hope Jewelry



BEAUTIFUL one of a kind art to wear creations that give back!
Each purchase benefits the Ovarian Cancer Research Fund!


Feel Teal Twibbon 2016


I cannot emphasise enough the importance of “awareness” when it comes to informing the public about ovarian cancer.
As an advocate/campaigner, I’ve spent the past 16 years attempting various methods of communicating this crucial information and have witnessed great movement during the years within the community, all proudly displaying their TEAL support.
Now for those of you who may be unfamiliar with the colour TEAL, please allow me to make things clearer.

Globally we know to “Think Pink” for Breast cancer and there’s a constant source of funding flowing as a result-
For Ovarian cancer to achieve the same status, “Feel Teal” came into existence.

It’s that simple.

But what can you do to help? That too is simple.
The Feel Teal Club invites you to add a Twibbon to your Twitter profile, showing your support for this cause.


When done, be sure to RETWEET and share share share!

From a whisper to a roar….ovarian cancer SILENT NO MORE!6b71d668bae4

World Cancer Day Event

Tomorrow is World Cancer Day…
Why not treat yourself or a friend to something beautiful , the gift that gives back!
20% of each purchase donates to T.E.A.L in their fight against Ovarian Cancer!
Lee’s Hope Jewelry celebrates February 4, 2016 World Cancer Day…give the gift that gives back!
Online Sale only

This slideshow requires JavaScript.

Designed for a cause

A big part of my life involves raising awareness to Ovarian Cancer, the disease which claimed my mother’s life in 2000.
Along my “awareness” road I have encountered others much like me, doing their bit to ensure the female population know the signs & warnings of this dreadful cancer.
One such person is my sweet friend, Sarah Schlichter Weighknech.
Sarah lost her beautiful sister Lee, to Ovarian Cancer almost seven years ago and to this day spends time doing what her sister loved the most…creating jewelry.

Lee’s Hope Jewelry creates unique designs for every lady, every day with a percentage of each sale contributed to Ovarian Cancer networks as their gift of support.
Which design will YOU choose?

Right now all mismatched earrings are on sale at a low crazy price of $25.
Show off your stylish jewelry while showing your support!

To order all that is required is an email to receive your Paypal invoice.

Age and ovarian cancer

female_symbol_color_colour_dark_turquoiseOvarian cancer is cancer of the ovaries. Women are born with two ovaries, one on each side of the uterus. A woman’s ovaries are small, about the size of an almond. Though small, they’re responsible for many reproductive functions.

Ovarian cancer can be very difficult to detect and diagnose. Many of the symptoms of ovarian cancer are similar to symptoms caused by much less serious problems, including indigestion and bloating. Because the ovaries are deep within the pelvis, there often are neither signs nor symptoms of early ovarian cancer. Some cases of ovarian cancer will not be diagnosed until the cancer has spread to a woman’s abdomen or elsewhere within the pelvis. Unfortunately, ovarian cancer that has progressed this far is very difficult to treat. While the cancer remains confined to the ovaries, doctors have an easier chance of treating it. Advanced stages of ovarian cancer are frequently fatal.

Ovarian cancer occurs most frequently in older women. Ovarian cancer rates are highest in women aged 55-64 years.
The median age at which women are diagnosed is 63, meaning that half of women are younger than 63 when diagnosed with ovarian cancer and half are older. Ovarian cancer is rare in women younger than 40. However, it’s also possible for younger women and even adolescent girls to be diagnosed with a type of ovarian cancer.
According to research many cases in younger women have germ cell tumors, which is a different type of tumor from [the more common] epithelial tumor.


For further reading please view these links:


All women are at risk of ovarian cancer
Awareness of the early warning signs of the disease could save lives
Diagnosis at an early stage vastly improves a woman’s chance of survival
Ovarian cancer is often diagnosed at a late stage.
Many women mistakenly believe the cervical smear test (Pap test) will detect ovarian cancer

We can now!

Many of us share a bundle of emotions when discussing ovarian cancer-
Many of us feel angry, many of us feel like we were “ripped off”….we hurt because we either feel more could have been done, or possibly because we believe we lacked the right information and support.
Like me, many struggle with the fact they had little time to find answers…there just didn’t seem to be anyone with the answers we were looking for and when we began the search, there seemed little anyone could do.
We feel our anger “justified”, mainly because WE were never told about ovarian cancer.And when this disease takes our loved-one from us, the anguish leads to “blame”. Why didn’t that doctor know? Why didn’t they do more? Why didn’t “I” do more?
And on and on it goes…..until we hear of others like us….others going through the same thing, the same pain the same suffering.
Others who had also felt “in the dark” when it came to this cancer and all asking the same question: “What IS ovarian cancer?”
Years later, and we still have much that needs to be done in ensuring this cancer receives more exposure but we have made progress and we will continue to do so!
The best plan of action next to a cure, is prevention, and the best weapon we have in this battle is “awareness”.oc awareness 2

So…whenever we feel frustrated or angry that WE never knew, well…we know NOW.
Every time we wish WE could have done something…well, we can NOW.
You and I are now equipped with enough valuable information & resources to arm and protect others just like us and by doing so, enables THEM to pass it along.
I had made a promise….that no other woman would die in vain, and by spreading awareness I believe Ive kept that vow.
From a whisper to a roar….ovarian cancer, silent NO MORE!

measure of benefit-ovarian cancer

Ovarian Cancer: New Measure of Benefit Proposed

Veronica Hackethal, MD
January 07, 2015

For patients with ovarian cancer who are in remission, the probability of remaining disease-free improves considerably over time, and conditional disease-free survival might be a good estimate of prognosis for these patients, according to a new study.
The study, which was published in the December issue of Journal of Clinical Oncology, is the first to look at conditional disease-free survival in patients with ovarian cancer.
“We observed that at time of remission, the probability of staying disease-free for 3 more years was 48%. This increased to 98% for patients who had remained disease-free for 5 years after remission,” said lead author Brenda Diergaarde, PhD, assistant professor of epidemiology at the University of Pittsburgh Cancer Institute.
Prognosis usually improves over time, Dr Diergaarde pointed out. Traditional survival estimates, like overall survival (estimated at diagnosis) and disease-free survival (estimated at remission), might not apply to patients in remission for a certain period of time.
Conditional disease-free survival, however, takes into account changes in the probability of remaining disease-free over time, as well as the amount of time since achieving remission, Dr Diergaarde explained.
“Time elapsed since remission should be taken into account when making follow-up care decisions,” Dr Diergaarde emphasized. “Having more accurate information about the risk of recurrence will allow patients and clinicians to make better informed decisions regarding follow-up care after ovarian cancer treatment. It may also lead to a better quality of life [for patients] because a more accurate prognosis can ease their fears about the cancer coming back.”
Estimation of Conditional Disease-free Survival
In their study, Dr Diergaarde and colleagues used data from 404 patients with ovarian, fallopian, and peritoneum cancer who were diagnosed from 2003 to 2008 and who had achieved remission. All patients were part of the large case–control Hormones and Ovarian Cancer Prediction (HOPE) study.
The HOPE study involves patients from western Pennsylvania, eastern Ohio, and western New York who entered the study within 9 months of their diagnosis. Researchers gathered demographic and lifestyle information at study enrollmentImage1, and used medical records to obtain information on disease, treatment, and outcomes. They calculated disease-free survival as the amount of time between remission and recurrence, or date of last contact, and estimated conditional disease-free survival from cumulative disease-free survival estimates.
Most patients (96.8%) were white, and 5.5% had a family history of ovarian or breast cancer. Patients who had already survived 1, 2, 3, 4, or 5 years had a probability of 3 more years of recurrence-free survival of 63.8%, 80.5%, 90.4%, 97.0%, and 97.7%, respectively.
The probability of being disease-free 5 years after achieving remission increased from 44.6% at baseline to 63.3%, 80.5%, 92.4%, and 99.2%, respectively, 1, 2, 3, and 4 years into remission.
Although conditional disease-free survival always increases as the number of years spent in remission increases, certain subgroups in this study experienced larger increases, Alexia Lasonos, PhD, a biostatistician at the Memorial Sloan Kettering Cancer Center in New York City, pointed out in an accompanying podcast.
“The increase was larger for patients above 65 years of age, patients with advanced-stage disease, serous histology, and poorly differentiated tumors,” Dr Lasonos said. “This indicates that conditional disease-free survival improves most for patients who initially had the poorest prognosis.”
At the time of remission, disease-free survival estimates also varied, depending on age, stage, histology, and grade. These factors were important for patients who remained in remission for 3 years, she explained.
“If a patient was still in remission 4 years later, her age, stage, histology, and grade at diagnosis were no longer diagnostic in terms of disease-free survival,” she added. “What mattered most at that time is the fact that the patient had been in remission for 4 years.”
Dr Lasonos urged caution, though, when interpreting the results of this study. Conditional disease-free survival estimates always have a larger degree of uncertainty than baseline estimates, she noted. This is because fewer patients remain in remission over time.
In addition, results suggest that risk for recurrence is significantly higher in patients on maintenance chemotherapy. However, high-risk patients are more likely to have received maintenance chemotherapy, which could have biased these results. Other limitations of the study could have been its observational nature and its lack of a standardized surveillance group.
Nevertheless, Dr Lasonos commended Dr Diergaarde’s team for their work.
“With new successful treatments and advances in immunotherapy that have extended time in remission for this patient population, these conditional estimates become more relevant for ovarian cancer patients,” Dr Lasonos emphasized.
Future research will need to focus on developing prognostic tools that take time in remission into account, she concluded.
‘Important Contribution’
“This is an important contribution to both the literature and the discussion of the way survival outcomes might optimally be presented to cancer patients,” said Maurie Markman, MD, senior vice president for clinical affairs at the Cancer Treatment Centers of America in Philadelphia, and Medscape video blogger for Markman on Oncology, who was not involved in the study.8796875_f520
“Until this report, we really did not have a solid strategy to develop specific numbers that could be provided to patients who have already survived a period of time without recurrence,” Dr Markman explained. “Hopefully, in the future, the concept of conditional disease-free survival will become a regular part of discussions within the oncology community and with patients,” he said.
Dr Diergaarde and Dr Lasonos have disclosed no relevant financial relationships. Dr Markman reports receiving fees from Celgene, Caris Life Sciences, Novartis, sanofi-aventis, Amgen, and Genentech.
Article courtesy www.medscape.com/